FDA approves Gazyva as first treatment for primary membranous nephropathy
The FDA approves Gazyva as the first treatment for primary membranous nephropathy; AstraZeneca's weekly self-injected Klygefa is approved for myasthenia gravis and CMS extends its hospice enrollment moratorium.